Bortezomib in patients with renal impairment

References

• Bladé J, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, et al.. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998;158:1889–93.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al.. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21–33.
   PubMed Web of Science ®Google Scholar
• Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma — a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994;53:207–12.
   PubMed Web of Science ®Google Scholar
• Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, et al.. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 2007;48:337–41.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008;22:1485–93.
   PubMed Web of Science ®Google Scholar
• Munshi NC. Plasma cell disorders: an historical perspective. Hematology Am Soc Hematol Educ Program 2008:297.
   Google Scholar
• Abbott KC, Agodoa LY. Multiple myeloma and light chain associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2001;56:207–10.
   PubMed Web of Science ®Google Scholar
• Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, et al.. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 — Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005;23:9219–26.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al.. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–20.
   PubMed Web of Science ®Google Scholar
• Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521–6.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Anderson KC. Preclinical studies of novel targeted therapies. Hematol Oncol Clin North Am 2007;21:1071–91viii–xi.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al.. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557–60.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, et al.. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006;91:1498–505.
   PubMed Web of Science ®Google Scholar
• Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009;374:324–39.
   PubMed Web of Science ®Google Scholar
• Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, et al.. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos 2005;33:771–7.
   PubMed Web of Science ®Google Scholar
• Mulkerin D, Remick S, Takimoto C, Ivy P, Karol M. Safety, tolerability, and pharmacology of bortezomib in cancer patients with renal failure requiring dialysis: results from a prospective phase 1 study. Blood (ASH Annual Meeting Abstracts) 2007;110:Abstract 3477.
   Web of Science ®Google Scholar
• Roussou M, Kastritis E, Migkou M, Psimenou E, Grapsa I, Matsouka C, et al.. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 2008;49:890–5.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E, et al.. VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 2009;27:6086–93.
   PubMed Web of Science ®Google Scholar
• Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G, et al.. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol 2010;84:223–8.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, et al.. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 2005;103:1195–200.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, et al.. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007;109:2604–6.
   PubMed Web of Science ®Google Scholar
• San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al.. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008;22:842–9.
   PubMed Web of Science ®Google Scholar
• Huber JM, Tagwerker A, Heininger D, Mayer G, Rosenkranz AR. The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2009;297:F451–60.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V, et al.. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007;109:2767–72.
   PubMed Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al.. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–73.
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al.. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137–47.
   PubMed Web of Science ®Google Scholar
• Bauer C, Melamed ML, Hostetter TH. Staging of chronic kidney disease: time for a course correction. J Am Soc Nephrol 2008;19:844–6.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al.. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005;106:2977–81.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al.. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007;109:3489–95.
   PubMed Web of Science ®Google Scholar
• Mateos MV, San Miguel JF. Bortezomib in multiple myeloma. Best Pract Res Clin Haematol 2007;20:701–15.
   PubMed Web of Science ®Google Scholar
• Gerecitano J, Goy A, Wright J, MacGregor-Cortelli B, Neylon E, Gonen M, et al.. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol 2006;134:391–8.
   PubMed Web of Science ®Google Scholar
• Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, et al.. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006;107:3492–4.
   PubMed Web of Science ®Google Scholar
• Pitini V, Arrigo C, Altavilla G, Naro C. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis? Leuk Res 2007;31:1027–8.
   PubMed Web of Science ®Google Scholar
• Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 2001;7:1291–7.
   PubMed Web of Science ®Google Scholar
• Pasparakis M. IKK/NF-kappaB signaling in intestinal epithelial cells controls immune homeostasis in the gut. Mucosal Immunol 2008;1(Suppl 1):S54–7.
   PubMedGoogle Scholar
• Guijarro C, Egido J. Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int 2001;59:415–24.
   PubMed Web of Science ®Google Scholar
• Zordoky BN, El-Kadi AO. Role of NF-kappaB in the regulation of cytochrome P450 enzymes. Curr Drug Metab 2009;10:164–78.
   PubMed Web of Science ®Google Scholar
• Yazici Y. Some concerns about adverse event reporting in randomized clinical trials. Bull NYU Hosp Jt Dis 2008;66:143–5.
   PubMedGoogle Scholar